Under the agreement, the U.S. government will pay French drugmaker Sanofi and British pharmaceutical company GlaxoSmithKlein up to $ 2.1 billion in exchange for providing enough vaccines for 50 million people, with the option to purchase an additional 500 million doses. Will be carried out under what the administration calls “Operation Earp Speed”, which aims to get the Cubid 19 vaccine to the market quickly – even before the end of 2020.
“Today’s investment supports our leading vaccine candidate, Sanofi and GSK companies, including during clinical trials and production, with the potential to bring hundreds of millions of safe and effective vaccines to U.S. citizens,” said Alex Azar, secretary of the U.S. Department of Health and Human Services.
The corona virus, which first appeared in China, has so far infected 4.7 million people across the U.S., killing 156,000 people, according to Reuters. The U.S. Centers for Disease Control predicts that by August 22, the death toll in the U.S. will reach 168,000 by 182 thousand and that the mortality rate will increase in the states of Alabama, Kentucky, New Jersey, Puerto Rico, Tennessee and Washington. The center also published a study showing that nearly half of the faculty and campers at a Georgia camp site contracted Cubid 19 about a week and a half ago. According to this study, “children of all ages are prone to contracting Covid 19, and may play an important role in transmitting the disease, compared to previous beliefs.”
The White House’s senior adviser on Covid 19’s affairs, Dr. Deborah Brix, said the virus appears to be spreading from “sun belt” states like Arizona, California and Florida, toward the Midwest and especially to Ohio, Kentucky, Tennessee, Missouri, Kansas and Nebraska.
About a week and a half ago, Pfizer and BioNTech announced an agreement with the United States to purchase the vaccine that the companies are developing against the corona virus. And its effectiveness. This is the largest agreement to date between the government and companies in the race to develop a vaccine for the virus.